In particular, the expression values of TLR-2, TLR-3, TLR-4, and TLR-9 on CD3-CD56+ cells increased proportionally with the tumor stage, suggesting that these receptors may be functional as diagnostic and prognostic biomarkers in assessing the progression of GC. This evidence concerns the gene TLR4 and neoplasm.